- 作者：Carolyn N. Krasner ; Andres Poveda ; Thomas J. Herzog ; Jan B. Vermorken ; Stanley B. Kaye ; Antonio Nieto ; Pilar Lardelli Claret ; Youn Choi Park ; Trilok Parekh ; Bradley J. Monk
- 关键词：Trabectedin ; Yondelis® ; Pegylated liposomal doxorubicin ; DOXIL® ; Relapsed ovarian cancer ; Patient-reported outcome
- 刊名：Gynecologic Oncology
- 出版年：2012
- 出版时间：October, 2012
- 年：2012
- 卷：127
- 期：1
- 页码：161-167
- 全文大小：553 K
Objective
Trabectedin in combination with PLD improves progression-free survival (PFS) and overall response rate (ORR) in comparison to PLD alone in patients with relapsed ovarian cancer (J Clin Oncol; 2010 28:3107-14). Here we report the impact of the treatment combination on patient-reported functional status and symptoms.Methods
Patient-reported outcome (PRO) questionnaires, EORTC-QLQ C30, OV28, and EQ-5D were completed by patients at screening and on Day 1 of every other treatment cycle starting with Cycle 1, and at the end-of-treatment visit.
Results
Of the 672 patients randomized in this study, 663 treated patients completed at least one of the baseline questionnaires. Median cycles of treatment was 6 (131 days) for the combination arm and 5 (143 days) for the monotherapy arm. Longitudinal data analyses showed no significant differences between the treatment arms for any of the pre-specified scales. Similar analyses of other scales, including Health Index scores and Health State on the Visual Analog Scale, support these findings. Start of subsequent therapy was significantly delayed in the combination arm compared with the monotherapy arm (p = 0.0032).
Conclusions
The addition of trabectedin to PLD led to little or no decrement in patient-reported functional status and symptoms in patients with relapsed ovarian cancer, as compared to treatment with PLD alone. The combination led to manageable and non©\cumulative overall toxicity with a fewer PLD-associated adverse events, and a significant improvement in PFS and ORR compared to single agent.